Literature DB >> 6529535

The first pass metabolism of nifedipine in man.

D G Waller, A G Renwick, B S Gruchy, C F George.   

Abstract

Oral administration of nifedipine (20 and 30 mg tablets) to six volunteers was associated with a bioavailability of 0.43 and the presence of its nitropyridine analogue in the plasma. This metabolite was present in only trace amounts in samples taken from the same volunteers following i.v. administration of nifedipine. The peak plasma concentrations and area under the plasma concentration-time curve suggest that the nitropyridine analogue is a major, first pass, metabolite of nifedipine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6529535      PMCID: PMC1463677          DOI: 10.1111/j.1365-2125.1984.tb02569.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  [Clinical study on the pharmacokinetics of radioactively labelled 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester].

Authors:  F A Horster; B Duhm; W Maul; H Medenwald; K Patzschke; L A Wegner
Journal:  Arzneimittelforschung       Date:  1972-02

2.  Determination of nifedipine in serum or plasma by reversed-phase liquid chromatography.

Authors:  P R Bach
Journal:  Clin Chem       Date:  1983-07       Impact factor: 8.327

3.  High-performance liquid chromatography of nifedipine, its metabolites and photochemical degradation products.

Authors:  P Pietta; A Rava; P Biondi
Journal:  J Chromatogr       Date:  1981-06-19

4.  Occurrence and measurement of nifedipine and its nitropyridine derivatives in human blood plasma.

Authors:  J Dokladalova; J A Tykal; S J Coco; P E Durkee; G T Quercia; J J Korst
Journal:  J Chromatogr       Date:  1982-09-10

5.  Determination of nifedipine in human plasma by capillary gas chromatography with nitrogen detection.

Authors:  M T Rosseel; M G Bogaert
Journal:  J Chromatogr       Date:  1983-11-25

6.  Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

Authors:  T S Foster; S R Hamann; V R Richards; P J Bryant; D A Graves; R G McAllister
Journal:  J Clin Pharmacol       Date:  1983-04       Impact factor: 3.126

  6 in total
  37 in total

1.  A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects.

Authors:  S Ueda; P A Meredith; C A Howie; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

2.  Ethnic differences in the pharmacokinetics of oral nifedipine.

Authors:  C H Ahsan; A G Renwick; B Macklin; V F Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 3.  The combination of slow-release nifedipine and atenolol for stable angina.

Authors:  D G Waller; V F Challenor
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women.

Authors:  Gabriela Campos de Oliveira Filgueira; Osmany Alberto Silva Filgueira; Daniela Miarelli Carvalho; Maria Paula Marques; Elaine Christine Dantas Moisés; Geraldo Duarte; Vera Lucia Lanchote; Ricardo Carvalho Cavalli
Journal:  Br J Clin Pharmacol       Date:  2017-01-29       Impact factor: 4.335

6.  The influence of food on the pharmacokinetics of 'biphasic' nifedipine at steady state in normal subjects.

Authors:  G H Rimoy; J R Idle; N K Bhaskar; P C Rubin
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

7.  Nifedipine, verapamil and cyclosporin A pharmacokinetics in children.

Authors:  M R Ogborn; J F Crocker; P C Grimm
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

8.  Slow release nifedipine plus atenolol in chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

9.  Haemodialysis does not affect the pharmacokinetics of nifedipine.

Authors:  H Martre; R Sari; A M Taburet; C Jacobs; E Singlas
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

10.  Clinical and rheological effects of nifedipine in Raynaud's phenomenon.

Authors:  D G Waller; V F Challenor; D A Francis; O S Roath
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.